Evidence map›Paper›PMID 36822114›Full record

SynthesisESMO open2023

A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic testing.

S Paiella, D Azzolina, D Gregori, G Malleo, T Golan, D M Simeone, M B Davis, P G Vacca, A Crovetto, C Bassi and 3 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in ESMO open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 6 countries.

S PaiellaGeneral and Pancreatic Surgery Unit, Pancreas Institute, University of Verona, Verona. Electronic address: https://twitter.com/Totuccio83.
D AzzolinaDepartment of Environmental and Preventive Science, University of Ferrara, Ferrara.
D GregoriUnit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Padova, Italy. Electronic address: https://twitter.com/gregoriDario.
G MalleoGeneral and Pancreatic Surgery Unit, Pancreas Institute, University of Verona, Verona. Electronic address: https://twitter.com/gimalleo.
T GolanOncology Institute, Sheba Medical Center at Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel.
D M SimeoneDepartment of Surgery, New York University, New York; Perlmutter Cancer Center, New York University, New York. Electronic address: https://twitter.com/MadameSurgeon.
M B DavisDepartment of Surgery and Surgical Oncology, Weill Cornell University, New York; Englander Institute of Precision Medicine, Weill Cornell University, New York, USA. Electronic address: https://twitter.com/MeliD32.
P G VaccaGeneral and Pancreatic Surgery Unit, Pancreas Institute, University of Verona, Verona. Electronic address: https://twitter.com/pvhdfm.
A CrovettoGeneral and Pancreatic Surgery Unit, Pancreas Institute, University of Verona, Verona. Electronic address: https://twitter.com/crovetto_a.
C BassiGeneral and Pancreatic Surgery Unit, Pancreas Institute, University of Verona, Verona.
R SalviaGeneral and Pancreatic Surgery Unit, Pancreas Institute, University of Verona, Verona. Electronic address: https://twitter.com/SalviaRobi.
A V BiankinWolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK; Faculty of Medicine, South Western Sydney Clinical School, University of NSW, Liverpool, Australia. Electronic address: andrew.biankin@glasgow.ac.uk.
R CasolinoWolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow. Electronic address: raffaella.casolino@glasgow.ac.uk.
Pancreas Centre (Canada) · CACornell University · USGlasgow Royal Infirmary · GBNew York University · USSheba Medical Center · ILUniversity of Ferrara · ITUniversity of Glasgow · GBUniversity of Padua · IT

Funding

Cancer Research UK A23526Cancer Research UK C29717/A17263Cancer Research UK C29717/A18484Cancer Research UK C596/A18076Cancer Research UK C596/A20921Medical Research CouncilWellcome Trust 103721/Z/14/Z
6 · The paper itself

Abstract

backgroundGermline BRCA1 and BRCA2 mutations (gBRCAm) can inform pancreatic cancer (PC) risk and treatment but most of the available information is derived from white patients. The ethnic and geographic variability of gBRCAm prevalence and of germline BRCA (gBRCA) testing uptake in PC globally is largely unknown. MATERIALS AND

methodsWe carried out a systematic review and prevalence meta-analysis of gBRCA testing and gBRCAm prevalence in PC patients stratified by ethnicity. The main outcome was the distribution of gBRCA testing uptake across diverse populations worldwide. Secondary outcomes included: geographic distribution of gBRCA testing uptake, temporal analysis of gBRCA testing uptake in ethnic groups, and pooled proportion of gBRCAm stratified by ethnicity. The study is listed under PROSPERO registration number #CRD42022311769.

resultsA total of 51 studies with 16 621 patients were included. Twelve of the studies (23.5%) enrolled white patients only, 10 Asians only (19.6%), and 29 (56.9%) included mixed populations. The pooled prevalence of white, Asian, African American, and Hispanic patients tested per study was 88.7%, 34.8%, 3.6%, and 5.2%, respectively. The majority of included studies were from high-income countries (HICs) (64; 91.2%). Temporal analysis showed a significant increase only in white and Asians patients tested from 2000 to present (P < 0.001). The pooled prevalence of gBRCAm was: 3.3% in white, 1.7% in Asian, and negligible (<0.3%) in African American and Hispanic patients.

conclusionsData on gBRCA testing and gBRCAm in PC derive mostly from white patients and from HICs. This limits the interpretation of gBRCAm for treating PC across diverse populations and implies substantial global and racial disparities in access to BRCA testing in PC.

Indexed as

BRCA2 ProteinPancreatic NeoplasmsGenetic TestingHumansMutationBRCA2 ProteinBRCAdisparitiesgermline testingpancreatic cancer

Identifiers

PMID36822114
PMCPMC10163165
OpenAlexW4321507085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.